trial · primary record
Camrelizumab plus apatinib CohortA
Gestational Trophoblastic Neoplasia
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 70 |
| Primary completion | 2027-01-01 |
| Primary endpoint | Cohort A: Complete remission rate |
| Registry ID | NCT05139095 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:43.946Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05139095
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.